fbpx
Medical Innovation Exchange

ASCO: I-Mab, Junshi's cancer combo performs best as a first-line NSCLC treatment, with signals for CD73 as a biomarker

https://www.fiercebiotech.com/clinical-data/asco-i-mabs-antibody-combo-performs-best-first-line-treatment-patient-pool-may-be

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.